A gut response. The next generation of type 2 drugs.
Kordella
Terri
T
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D000077270:Exenatide; D054439:Ghrelin; D005934:Glucagon / Q000627:therapeutic use; D052216:Glucagon-Like Peptide 1; D004763:Glucagon-Like Peptides / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D010446:Peptide Fragments / Q000627:therapeutic use; D036361:Peptide Hormones / Q000627:therapeutic use; D019894:Peptide YY / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D011498:Protein Precursors / Q000627:therapeutic use; D014481:United States; D014688:Venoms / Q000627:therapeutic use
D054439:Ghrelin; D007004:Hypoglycemic Agents; D010446:Peptide Fragments; D036361:Peptide Hormones; D010455:Peptides; D011498:Protein Precursors; D014688:Venoms; D019894:Peptide YY; D004763:Glucagon-Like Peptides; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D000077270:Exenatide